RT Journal Article
T1 Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS
A1 Spelman, Tim
A1 Kalincik, Tomas
A1 Jokubaitis, Vilija
A1 Zhang, Annie
A1 Pellegrini, Fabio
A1 Wiendl, Heinz
A1 Belachew, Shibeshih
A1 Hyde, Robert
A1 Verheul, Freek
A1 Lugaresi, Alessandra
A1 Havrdova, Eva
A1 Horakova, Dana
A1 Grammond, Pierre
A1 Duquette, Pierre
A1 Prat, Alexandre
A1 Iuliano, Gerardo
A1 Terzi, Murat
A1 Izquierdo, Guillermo
A1 Hupperts, Raymond M. M.
A1 Boz, Cavit
A1 Pucci, Eugenio
A1 Giuliani, Giorgio
A1 Sola, Patrizia
A1 Spitaleri, Daniele L. A.
A1 Lechner-Scott, Jeannette
A1 Bergamaschi, Roberto
A1 Grand'Maison, Francois
A1 Granella, Franco
A1 Kappos, Ludwig
A1 Trojano, Maria
A1 Butzkueven, Helmut
A1 MSBase Investigators TOP Investiga, 
K1 Remitting multiple-sclerosis
K1 Long-term safety
K1 Patient selection
K1 Disease-activity
K1 Interferon-beta
K1 Double-blind
K1 Predictors
K1 Benefits
K1 Outcomes
K1 Risk
AB Background: We compared efficacy and treatment persistence in treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS) initiating natalizumab compared with interferon-beta (IFN-beta)/glatiramer acetate (GA) therapies, using propensity score-matched cohorts from observational multiple sclerosis registries. Methods: The study population initiated IFN-beta/GA in the MSBase Registry or natalizumab in the Tysabri Observational Program, had >= 3 months of on-treatment follow-up, and had active RRMS, defined as >= 1 gadolinium-enhancing lesion on cerebral MRI at baseline or >= 1 relapse within the 12 months prior to baseline. Baseline demographics and disease characteristics were balanced between propensity-matched groups. Annualized relapse rate (ARR), time to first relapse, treatment persistence, and disability outcomes were compared between matched treatment arms in the total population (n = 366/group) and subgroups with higher baseline disease activity. Results: First-line natalizumab was associated with a 68% relative reduction in ARR from a mean (SD) of 0.63 (0.92) on IFN-beta/GA to 0.20 (0.63) (p [signed-rank] = 3 months of on-treatment follow-up, and had active RRMS, defined as >= 1 gadolinium-enhancing lesion on cerebral MRI at baseline or >= 1 relapse within the 12 months prior to baseline. Baseline demographics and disease characteristics were balanced between propensity-matched groups. Annualized relapse rate (ARR), time to first relapse, treatment persistence, and disability outcomes were compared between matched treatment arms in the total population (n = 366/group) and subgroups with higher baseline disease activity. Results: First-line natalizumab was associated with a 68% relative reduction in ARR from a mean (SD) of 0.63 (0.92) on IFN-beta/GA to 0.20 (0.63) (p [signed-rank] = 1 gadolinium-enhancing lesion on cerebral MRI at baseline or >= 1 relapse within the 12 months prior to baseline. Baseline demographics and disease characteristics were balanced between propensity-matched groups. Annualized relapse rate (ARR), time to first relapse, treatment persistence, and disability outcomes were compared between matched treatment arms in the total population (n = 366/group) and subgroups with higher baseline disease activity. Results: First-line natalizumab was associated with a 68% relative reduction in ARR from a mean (SD) of 0.63 (0.92) on IFN-beta/GA to 0.20 (0.63) (p [signed-rank] = 1 relapse within the 12 months prior to baseline. Baseline demographics and disease characteristics were balanced between propensity-matched groups. Annualized relapse rate (ARR), time to first relapse, treatment persistence, and disability outcomes were compared between matched treatment arms in the total population (n = 366/group) and subgroups with higher baseline disease activity. Results: First-line natalizumab was associated with a 68% relative reduction in ARR from a mean (SD) of 0.63 (0.92) on IFN-beta/GA to 0.20 (0.63) (p [signed-rank]
PB Lippincott williams & wilkins
SN 2163-0402
YR 2016
FD 2016-04-01
LK http://hdl.handle.net/10668/19139
UL http://hdl.handle.net/10668/19139
LA en
DS RISalud
RD Apr 9, 2025